Fox Run Management’s Standard BioTools LAB Stock Holding History

Fox Run Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10,101	Closed	-$75K	–	243
2020 Q3	$75K	Buy	+10,101	New	+$69.7K	0.19%	152

Other funds holding LAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Fox Run Management's LAB Position: Q4 2020 in Review

Fox Run Management sold out of Standard BioTools (LAB) in Q4 2020, closing a stake of 10,101 shares — an estimated $75K sold.

Fox Run Management first reported a position in LAB in Q3 2020 and held it in 1 quarter. The position peaked at $75K in Q3 2020. 145 funds tracked by Wall St. Rank hold LAB as of Q4 2020.

Fox Run Management reported no remaining Standard BioTools position as of Q4 2020 after selling out during the quarter.
Fox Run Management sold 10,101 Standard BioTools shares in Q4 2020, an estimated $75K.
Fox Run Management first reported a position in Standard BioTools in Q3 2020 and held it in 1 quarter.
Fox Run Management's Standard BioTools position peaked at $75K in Q3 2020.
145 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2020.

Based on Fox Run Management's 13F filing for Q4 2020, filed 8 Feb 2021.